The predicted functional impact of these mutations, their segregation with the phenotype, and the absence of these variants in healthy controls provided strong support for the role of BMPR2 and the TGF-β signalling pathway in the pathobiology of PAH. This evidence concerns the gene BMPR2 and pulmonary arterial hypertension.